GLP-1s move into mainstream

Amazon is pushing weight-loss drugs into mainstream retail medicine, while the Food and Drug Administration has also cleared the first GLP-1 pill for obesity. (health.amazon.com) (accessdata.fda.gov) GLP-1 drugs mimic a gut hormone that slows stomach emptying and acts on brain centers that regulate hunger, according to Amazon One Medical’s patient information. Amazon says patients can sign up online, meet with a licensed provider, and, if prescribed, get either a pill or an injectable sent to a preferred pharmacy. (health.amazon.com) On Amazon’s new weight-loss page, the company says the program includes a dedicated provider, ongoing follow-ups, insurance and prior-authorization support, and “free delivery and transparent Prime pricing” if patients use Amazon Pharmacy. Amazon lists semaglutide and tirzepatide injections, plus semaglutide and Eli Lilly’s orforglipron pill, sold as Foundayo, among the options providers may consider. (health.amazon.com) The shift puts obesity treatment in the same consumer-facing channel Amazon already uses for urgent telehealth and prescription renewals. One Medical says Prime members can buy membership for $99 a year, while one-time on-demand virtual care starts at $29 or $49 depending on the visit type. (health.amazon.com 1) (health.amazon.com 2) The Food and Drug Administration’s updated Wegovy label now covers both injection and tablet forms for long-term weight reduction in adults with obesity, or adults who are overweight with at least one related condition. The label also says the tablet can be used, with diet and exercise, to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov) That label matters because injections have dominated the obesity market since Wegovy’s 2021 launch, and many patients have delayed treatment because of needle aversion, access bottlenecks, or insurance paperwork. Amazon’s program is built around those same friction points: online intake, prior-authorization help, refill support, and home delivery. (fda.gov) (health.amazon.com 1) (health.amazon.com 2) Safety warnings have not changed with the easier access. The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents and says the drug is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) The Food and Drug Administration also approved a higher-dose Wegovy injection, 7.2 milligrams, on March 19, 2026, adding another option for adults who need more weight loss than earlier doses delivered. The agency said the most common side effects were gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain. (fda.gov) The result is a market that now looks less like a specialty clinic and more like ordinary primary care: a telehealth intake, a prescription decision, and a package at the door. (health.amazon.com)